The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

The FDA has approved Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohn’s disease in adults. Clinical ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® ...

Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of human interleukin (IL)-23.

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

FDA approves Eli Lilly's Omvoh for Crohn's disease, showing strong Phase 3 results in clinical remission and intestinal ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for ...